Health Care/Hospital
Hope Rising in Hainan: International NUT Carcinoma Center Launches in Boao
BOAO, China, Jan. 29, 2026 /PRNewswire/ -- The International NUT Carcinoma Diagnosis and Treatment Center has been inaugurated at Boao International Hospital. Established through a collaboration between Boao International Hospital and Chongqing University Three Gorges Hospital, this center tackle...
2026-01-29 20:00
3950
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
- Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study - The exceptional efficacy of denifanstat (ASC40) observed in the Company's previously reported placebo-controlled Phase III trial couple...
2026-01-29 19:00
4852
Singapore hosts its first Global Health Film Festival, spotlighting pandemic and planetary health
The two-evening programme on 27-28 January at The Ngee Ann Kongsi Auditorium at the SingHealth Duke-NUS campus convened clinicians, students, policymakers and partners to focus on the importance of outbreak preparedness andplanetary health SINGAPORE, Jan. 29, 2026 /PRNewswire/ -- Singapore has ho...
2026-01-29 14:42
4574
Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"
HONG KONG, Jan. 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled "Spotlight On: The Drugs That Will Shape 2026", providing an in-depth analysis of 20 key drugs poised to define the trajectory of the ...
2026-01-29 12:51
4009
WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody
SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announced a strategic collaboration for the development and manufacturing of SND006, a novel bispecific ...
2026-01-29 10:39
6623
Bupa and Tencent Launch Hong Kong's First Palm-based Check-in Service for Enhanced Healthcare Experiences
AI-powered palm verification set to deliver seamless, contactless and hygienic check-in journeys for patients at Bupa's healthcare centres HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Tencent in collaboration with Bupa Hong Kong ("Bupa"), today officially launched Hong Kong's first palm verification...
2026-01-29 10:23
5372
QureBio Ltd. to Present at ASCO 2026 its Q-1802 Phase II Clinical Results
SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- QureBio Ltd., a clinical-stage biotech company focusing on development of bispecific antibodies and other engineered Biopharmaceuticals for the treatment of cancer, inflammation, and other serious disorders, today revealed in 2026 ASCO abstract submission a...
2026-01-29 10:21
3889
SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family
* Global phase 1/2 clinical trial initiated for GBP511, a vaccine targeting the Sarbecovirus Family * Next-generation vaccine leveraging SKYCovione's recombinant protein-based platform and nanoparticle technology * SK bioscience will continue to strengthen a Mid- to Long-Term global vaccine...
2026-01-29 10:10
5148
Nona Biosciences Co-founds Innovative Alliance for Translational Medicine in Immunological Diseases, Advancing a New IIT-Driven Ecosystem
CAMBRIDGE, Mass., Jan. 28, 2026 /PRNewswire/ -- Recently, as a core co-founder and co-organizer, Nona Biosciences participated in the launch of the "Innovative Alliance for Translational Medicine in Immunological Diseases" (the "Alliance") and attended its inauguration ceremony. The Alliance brin...
2026-01-29 09:00
3248
First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients
MELBOURNE, Australia, Jan. 29, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in the Phase 3 registration study of TLX591-Px (Illuccix®, Kit for the preparation of68Ga-PSMA-11) for prostate cancer imaging i...
2026-01-29 07:43
4330
REPROCELL Launches StemEdit - Clinical Gene Editing Services and New iPSC Lines Using AI-Designed editing tools
BELTSVILLE, Md., Jan. 29, 2026 /PRNewswire/ -- REPROCELL today announced the commercial launch ofStemEdit, its clinical gene editing services and new gene-edited iPSC product lines leveragingOpenCRISPR-1™, an AI-designed genome editing system licensed from Profluent (Emeryville, CA, USA). StemEd...
2026-01-28 22:00
4699
NYSE Content Advisory: Pre-Market Update + First Lady Melania Trump to Ring NYSE Bell for Doc 'Melania'
NEW YORK, Jan. 28, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market Update + First Lady Melania Tr...
2026-01-28 21:55
7055
Global Appeal 2026: Education as the Key to Ending Leprosy Stigma and Discrimination
— Launch Event in Brussels Will Be Live-Streamed Worldwide — TOKYO, Jan. 28, 2026 /PRNewswire/ -- The transformative power of education in replacing fear with knowledge and prejudice with empathy lies at the heart of the Global Appeal 2026 to End Stigma and Discrimination against Persons Affect...
2026-01-28 21:00
3148
Samsung Biologics receives EcoVadis Platinum, the highest sustainability rating
* Ranked in the top one percent among more than 150,000 companies assessed globally * Recognized for strengthened sustainability management across all four assessment categories INCHEON, South Korea, Jan. 28, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract developm...
2026-01-28 20:00
4646
Sciwind Biosciences Published T2DM Phase III EECOH-1 Trial Results of Ecnoglutide in Nature Communications
HANGZHOU, China, Jan. 28, 2026 /PRNewswire/ -- Recently, the results of the pivotal Phase III clinical trial (EECOH-1) of ecnoglutide injection, developed by Sciwind Biosciences Co., Ltd. ("Sciwind"), for the monotherapy of type 2 diabetes (T2DM), have been published in Nature Communications. Con...
2026-01-28 19:39
4214
CHCC 2026 Opens Registration, Offering a One-Stop Platform for Hospital Construction Solutions and Real-World Applications
TIANJIN, China, Jan. 28, 2026 /PRNewswire/ -- The 27th China Hospital Construction Conference & International Hospital Build and Infrastructure Exposition (CHCC 2026), a globally recognized hospital construction event, will be held from May 23 to 25, 2026, at the National Convention and Exhibitio...
2026-01-28 15:01
4363
Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More
Hanmi Signs Exclusive Partnership with New Mexican Partner Laboratorios Sanfer, Covering Efpeglenatide and Diabetes Treatments SEOUL, South Korea, Jan. 27, 2026 /PRNewswire/ -- Hanmi is accelerating its global market entry with efpeglenatide, Korea's first domestically developed GLP-1 class obes...
2026-01-28 12:08
3856
US FDA Approves First Daily Oral GLP‑1 Treatment for Weight Management, Showing Comparable Results to Injectable Therapy
The US Food and Drug Administration (FDA) has approved Novo Nordisk's new once-daily pill for weight management, designed to help people reduce excess body weight and maintain weight reduction over the long term. In clinical trials, patients achieved an average weight reduction of 16.6% from base...
2026-01-28 10:45
5542
Singapore Eye Research Institute tops ScholarGPS rankings in Ophthalmology
* The Institute has placed #1 in ophthalmology among all non-academic institutes, and #2 in the same field among all institutes, globally. SINGAPORE, Jan. 27, 2026 /PRNewswire/ -- The Singapore Eye Research Institute (SERI) has achieved a landmark milestone inDecember 2025 by securing first pla...
2026-01-28 10:00
3016
Organizations Without AI Security Policies Are Already Behind, Warns Armor
Armor releases AI governance framework to address critical policy gap as
enterprise AI adoption accelerates
DALLAS, Jan. 28, 2026 /PRNewswire/ -- Armor, a leading provider of
cloud-nativemanaged detection and response (MDR)
2026-01-28 02:21
3541
Week's Top Stories
Most Reposted
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 321 media titles]
2026-02-16 10:00
Ascentium Acquires Clara, Expanding into the Abu Dhabi Global Market (ADGM) and Strengthening its Middle East Presence
[Picked up by 310 media titles]
2026-02-12 14:00
Carro unveils quirky generative AI ad campaign highlighting its 'Surprisingly Short' AI-enabled car-selling process
[Picked up by 296 media titles]
2026-02-11 11:00
Vizzio Technologies Strengthens Leadership As Global Growth Accelerates
[Picked up by 294 media titles]
2026-02-11 14:59
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 275 media titles]
2026-02-17 19:12
Most Read
Datasea Reports Second Fiscal Quarter 2026 Results
2026-02-12 22:20
7325
eufy Raises the Bar for Home Cleaning with Omni C28, Delivering One-Pass-Clean Performance with HydroJet™ Self-Clean Roller Mop
2026-02-14 10:00
6915
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell
2026-02-12 21:56
6401
